Day 2, Tuesday, November 19, 2024 - ET (Eastern Time, GMT-05:00)
Day 2, Tuesday, November 19, 2024 - ET (Eastern Time, GMT-05:00)
- Chris Dowd - Senior Vice President, ConnectiveRx
National healthcare policy trends and legislative changes continue to be top-of-mind for many industry stakeholders in the access and reimbursement space.
- Deep dive into recent state regulations impacting 340B pricing, copay assistance and patient access to medications
- Discuss the proposed change by CMS to allow "stacking" of discounts and the respective implications on manufacturing distribution strategies and copay
- Outline the key provisions of the proposed transparency bill in Congress regarding copay assistance program
- Ashar Hasan - CEO, Medmonk
Hear directly from U.S. attorneys on trends of upcoming areas of focus and enforcement for 2024 and beyond, specifically looking at guidance on field-based roles, prior authorization and other focal points.
- Steven Sharobem - Assistant United States Attorney, US Attorney’s Office, District of Massachusetts
- Charlene Fullmer - Assistant United States Attorney, US Attorney’s Office, Eastern District of Pennsylvania
- Overview of common coding systems (e.g., CPT, ICD-10) and their relevance
- Key considerations in structuring bills for clear communication with patients and Incorporating transparency in billing to enhance patient understanding and compliance
- Utilizing advanced software and technologies for streamlined coding and billing processes
- Staying abreast of legal requirements in coding and billing practices
- Industry best practices in copay optimization through coding accuracy and effective billing
- Lilian Buch - Director, Reimbursement Strategy, Amgen
- Ticia Cawley - Vice President, Client Solutions, ConnectiveRx
- Jessica Cortez - Principal, Avalere
In today’s complex landscape, the considerable financial burden of high-cost treatments presents ongoing barriers not only for patients, but also for pharmaceutical companies working to bring therapies to market. To effectively address these challenges, it’s crucial to adopt a customized affordability approach that considers the diverse needs of patients and the unique characteristics of drug classifications. Enhanced copay programs, supported by a comprehensive pharmacy network, play a vital role in improving patient access to necessary medications. Discuss ways to help ensure innovative affordability solutions are comprehensive and tailored to meet the specific needs through integrated actionable data, effective brand safeguards, and specialized expertise throughout the brand lifecycle.
- Megan Wetzel - Senior Director, Affordability Solutions, CoverMyMeds
Copay adjustment programs, encompassing maximizers, accumulators, and alternative funding programs, have become a complex landscape for patients, manufacturers, and insurers. This session will dissect these programs, describe the impact on patients, and provide an update on regulatory and legislative activity to address the issues.
- Rachel Klein - Deputy Executive Director, The AIDs Institute
Across the board, the healthcare industry has seen a shift in the overall money funnel and many companies are facing strict budget constraints. In turn, manufacturers are looking to invest later in their processes in order to derisk earlier. During this session, learn how to weigh the costs of innovation, ensuring that your organization remains dynamic, forward thinking and patient centric even amidst financial limitations.
- Khawar Khokhar - Founder, CEO, SAKS Health
- John Harlow - Chief Commercial Officer, Melinta Therapeutics
- Doug Jordan - Senior Director, Payer Marketing & Strategy, Bausch + Lomb
- Take a look at the different states that have enacted comprehensive privacy legislations and their respective implications
- Ensure that your copay data is being stored and used in a way that is appropriate and compliant
- Understand the types of data that manufacturers can, and cannot, have access to and how to use such data to improve your provided services
- Strategize on how to assess, and reassess, should you encounter firewalls surrounding Patient Health Information (PHI)
- Discuss HIPAA, including the types and number of signatures that should be required on your patient services form
- Jon Westlund - Senior Privacy Counsel, Pfizer
- Jami Vibbert - Chair, Privacy, Cyber & Data Strategy Group, Arnold & Porter